Morning Edition · №
Medicine

Alzheimer's May Start Shrinking Two Brain Regions a Decade Before Memory Loss, Johns Hopkins Study Finds

Brain scans show the entorhinal cortex and amygdala losing tissue earlier than the hippocampus, the region doctors traditionally watch — a potential early-warning signal tied to Alzheimer's hallmark tau protein.

Alzheimer's May Start Shrinking Two Brain Regions a Decade Before Memory Loss, Johns Hopkins Study Finds
— Photograph: Vitaly Gariev / Unsplash. Illustrative: a doctor reviewing a brain scan, not from this study.
SHARE X f in ⧉

Alzheimer's disease may begin altering the brain nearly a decade before memory problems appear — and the earliest warning signs may show up in two regions doctors don't typically examine, according to a new study from Johns Hopkins University. Researchers there found that the entorhinal cortex and the amygdala — structures involved in memory retrieval and emotional processing — began losing tissue earlier than the hippocampus, the region most commonly scanned for signs of Alzheimer's.

The findings, published in the journal NeuroImage Reports and also being presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience, come from hundreds of MRI and PET scans drawn from two long-running studies: the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals project. Those scans tracked people across the disease's course, from those with no symptoms to those with mild cognitive impairment to patients who eventually died of Alzheimer's.

A Decade of Warning, Largely Unused

In both groups the researchers studied, the pattern held: the entorhinal cortex and amygdala showed more relative tissue loss earlier in the disease process than the hippocampus did — even though the hippocampus has long been the structure doctors focus on when looking for Alzheimer's-related damage. Using PET imaging and digital pathology, the team also found that the areas of gray-matter shrinkage overlapped with regions showing a buildup of tau, the misfolded protein whose tangled accumulation is one of Alzheimer's defining hallmarks.

"We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms," said Michael Miller, a Johns Hopkins biomedical engineer and the study's senior author. "It's at least a 5-to-10-year play where your brain is changing. Imagine if we could start to treat the neurodegenerative changes at the 2, 3 or 4-year point rather than after 15 years when the changes are manifesting in memory symptoms."

The researchers frame the work as a step toward earlier detection rather than a treatment in itself — the goal, said co-author and Johns Hopkins Alzheimer's Disease Research Center director Marilyn Albert, is "to be able to treat individuals before the symptoms of Alzheimer's disease develop so that they may [be] delayed or even stopped." Because the analysis is observational and draws on existing imaging cohorts rather than a new clinical trial, it identifies an association between early regional atrophy and later disease progression rather than proving a causal mechanism — and any resulting screening approach would still need validation in broader, more diverse patient populations before reaching clinical practice.

SHARE THIS ARTICLE X Facebook LinkedIn Copy link
Samuel Okafor · Health & Medicine Correspondent

Covers health and medicine for UBStandard: drug approvals, clinical research and the systems that deliver care.

[email protected]
Related coverage Front page →